Celldex (NASDAQ: CLDX ) shares popped 13% this week. There wasn't really any news from the company this week; instead, the nice gains appear to be a continuation from momentum that started last week.
A Valentine's Day announcement had Celldex investors feeling good about prospects for the company's experimental drug CDX-301. A phase 1 study of the drug in hematopoietic stem cell transplantation yielded positive results. Volunteers in the study who took CDX-301 experienced large increases in CD34+ and dendritic cells, findings that bode well for improved transplant outcomes.
Celldex also has other potential winners that are farther along in development. In November, the company announced positive phase 2 results for rindopepimut in treating EGFRvIII-positive glioblastoma. It also released good results in December from a phase 2 study of CDX-011 in treating breast cancer.
After reading the MF article I lightly probed the other three companies to get a feel for their products, development pathway and future potential. What i surmised is that cldx is positioned right in the center of this whole movement. Infinity Pharma, Gilead Sciences and Pharmacyclics are all much bigger companies in the $40 -$90 range working in the same field and getting positive results from multiple directions. INFI GILD PCYC check them out and I think you will get a sense of whats to come for cldx. I'm kinda hoping that some of the new idiots on this board are right in their prognostications that cldx and the overall market are going to sell off only because I very much regret not having bought double the shares I currently own. I knew 18 months ago this was going to unfold as it is. Frustrating to look back, just didn't have the cash and there was a sense of higher risk back then even after DD and cross references. I appreciate the few posters who have insight and understanding of this market niche , Bio-Science, Thanks for your info and insights. Really wish I could buy a few K more shares....!
Frank, before long analysts will try to estimate first year earnings for Celldex after cdx-011 is approved. I bet the PE multiple will be quite high as I see CLDX as a high growth company. We could be talking about a very high stock price in 3 yrs or less.